News
-
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors
Tharimmune, Inc. appoints Vincent LoPriore to its Board of Directors to bolster strategic leadership and drive growth in immunology and oncology. The move reflects the company's commitment to enhancing its leadership team with experienced financial professionals -
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
Tharimmune, Inc. announces preclinical data on novel dual-target biologics HS1940 and HS3215 using EpiClick™ Technology to address cancer treatment needs -
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
Tharimmune received positive feedback from the FDA on the 505(b)(2) NDA submission for TH104 buccal film for opioid prophylaxis. Company progressing CMC plan for NDA requirements -
